检索结果-南通市图书馆

Current evidence on potential of adipose derived stem cells to enhance bone regeneration and future projection

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Stem Cells 2021年第9期13卷 1248-1277页

作者： Quang Le Vedavathi Madhu Joseph M Hart charles r farber Eli r Zunder Abhijit S Dighe Quanjun Cui Department of Orthopaedic Surgery University of Virginia School of MedicineCharlottesvilleVA 22908United States Orthopaedic Surgery research Thomas Jefferson UniversityPhiladelphiaPA 19107United States Center for Public Health Genomics University of VirginiaCharlottesvilleVA 22908United States Departments of Public Health Sciences and Biochemistry and Molecular Genetics University of VirginiaCharlottesvilleVA 22908United States Department of Biomedical Engineering University of VirginiaCharlottesvilleVA 22908United States

Injuries to the postnatal skeleton are naturally repaired through successive stepsinvolving specific cell types in a process collectively termed “bone regeneration”.Although complex, bone regeneration occurs through a series of well-orchestratedstages wherein endogenous bone stem cells play a central role. In most situations,bone regeneration is successful;however, there are instances when it fails andcreates non-healing injuries or fracture nonunion requiring surgical or therapeuticinterventions. Transplantation of adult or mesenchymal stem cells (MSCs) definedby the International Society for Cell and Gene Therapy (ISCT) as CD105+-CD90+CD73+CD45-CD34-CD14orCD11b-CD79αorCD19-HLA-Dr- is beinginvestigated as an attractive therapy for bone regeneration throughout the *** isolated from adipose tissue, adipose-derived stem cells (ADSCs), aregaining increasing attention since this is the most abundant source of adult stemcells and the isolation process for ADSCs is straightforward. Currently, there isnot a single Food and Drug Administration (FDA) approved ADSCs product forbone regeneration. Although the safety of ADSCs is established from their usagein numerous clinical trials, the bone-forming potential of ADSCs and MSCs, ingeneral, is highly controversial. Growing evidence suggests that the ISCT definedphenotype may not represent bona fide osteoprogenitors. Transplantation of bothADSCs and the CD105- sub-population of ADSCs has been reported to induce bone regeneration. Most notably, cells expressing other markers such as CD146,AlphaV, CD200, PDPN, CD164, CXCr4, and PDGFrα have been shown torepresent osteogenic sub-population within ADSCs. Amongst other strategies toimprove the bone-forming ability of ADSCs, modulation of VEGF, TGF-β1 andBMP signaling pathways of ADSCs has shown promising results. The U.S. FDAreveals that 73% of Investigational New Drug applications for stem cell-basedproducts rely on CD105 expression as the “positive” marker for adult stem cell

关键词： Mesenchymal stem cells Adipose-derived stem cells Endogenous stem cells Skeletal stem cells Bone regeneration

Transplantation of stem cell-derived astrocytes for the treatment of amyotrophic lateral sclerosis and spinal cord injury

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Stem Cells 2015年第2期7卷 380-398页

作者： charles Nicaise Dinko Mitrecic Aditi Falnikar Angelo C Lepore Laboratory Neurodegeneration and regeneration URPhy M-NARILISFaculty of MedicineUniversity of Namur Laboratory for Stem Cells Croatian Institute for Brain ResearchUniversity of Zagreb Department of Neuroscience Farber Institute for NeurosciencesSidney Kimmel Medical College at Thomas Jefferson University Medical College

Neglected for years, astrocytes are now recognized to fulfill and support many, if not all, homeostatic functionsof the healthy central nervous system(CNS). During neurodegenerative diseases such as amyotrophic lateral sclerosis(ALS) and spinal cord injury(SCI), astrocytes in the vicinity of degenerating areas undergo both morphological and functional changes that might compromise their intrinsic properties. Evidence from human and animal studies show that deficient astrocyte functions or loss-of-astrocytes largely contribute to increased susceptibility to cell death for neurons, oligodendrocytes and axons during ALS and SCI disease progression. Despite exciting advances in experimental CNS repair, most of current approaches that are translated into clinical trials focus on the replacement or support of spinal neurons through stem cell transplantation, while none focus on the specific replacement of astroglial populations. Knowing the important functions carried out by astrocytes in the CNS, astrocyte replacement-based therapies might be a promising approach to alleviate overall astrocyte dysfunction, deliver neurotrophic support to degenerating spinal tissue and stimulate endogenous CNS repair abilities. Enclosed in this review, we gathered experimental evidence that argue in favor of astrocyte transplantation during ALS and SCI. Based on their intrinsic properties and according to the cell type transplanted, astrocyte precursors or stem cell-derived astrocytes promote axonal growth, support mechanisms and cells involved in myelination, are able to modulate the host immune response, deliver neurotrophic factors and provide protective molecules against oxidative or excitotoxic insults, amongst many possible benefits. Embryonic or adult stem cells can even be genetically engineered in order to deliver missing gene products and therefore maximize the chance of neuroprotection and functional recovery. However, before broad clinical translation, further preclinical data

关键词： Neuroprotection Stem cell Cell therapy Astrocyte Transplantation Amyotrophic lateral sclerosis Spinal cord injury

Activation of rAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2022年第3期7卷 856-868页

作者： Qi Zhang Bridget riley-Gillis Lina Han Yanan Jia Alessia Lodi Haijiao Zhang Saravanan Ganesan rongqing Pan Sergej N.Konoplev Shannon r.Sweeney Jeremy A.ryan Yulia Jitkova Kenneth Dunner Jr Shaun E.Grosskurth Priyanka Vijay Sujana Ghosh charles Lu Wencai Ma Stephen Kurtz Vivian r.ruvolo Helen Ma Connie CWeng Cassandra Lramage Natalia Baran Ce Shi Tianyu Cai richard Eric Davis Venkata L.Battula Yingchang Mi Jing Wang Courtney D.DiNardo Michael Andreeff Jeffery W.Tyner Aaron Schimmer Anthony Letai rose Ann Padua Carlos E.Bueso-ramos Stefano Tiziani Joel Leverson relja Popovic Marina Konopleva Department of Leukemia The University of Texas MD Anderson Cancer CenterHoustonTXUSA AbbVie Inc. North ChicagoILUSA Institute of Hematology Chinese Academy of Medical Sciences&Peking Union Medical CollegeTianjinChina Department of Nutritional Sciences Department of PediatricsDepartment of OncologyDell Medical SchoolThe University of Texas at AustinAustinTX 78712USA Department of Cell Developmental&Cancer BiologyDivision of Hematology&Medical OncologyKnight Cancer InstituteOregon Health&Science UniversityPortlandORUSA Universite de Paris Institut de la Recherche Saint-Louis(IRSL)Inserm Unit 1131ParisFrance Dana-farber Cancer Institute BostonMAUSA Department of Hematopathology The University of Texas MD Anderson Cancer CenterHoustonTXUSA Princess Margaret Cancer Center TorontoONCanada High resolution Electron Microscopy Facility The University of Texas MD Anderson Cancer CenterHoustonTXUSA Department of Bioinformatics&Computational Biology The University of Texas MD Anderson Cancer CenterHoustonTXUSA Department of Hematology The First Hospital Affiliated Harbin Medical UniversityHarbinChina Department of Lymphoma&Myeloma research The University of Texas MD Anderson Cancer CenterHoustonTXUSA

Despite high initial response rates,acute myeloid leukemia(AML)treated with the BCL-2-selective inhibitor venetoclax(VEN)alone or in combinations commonly acquires *** performed gene/protein expression,metabolomic and methylation analyses of isogenic AML cell lines sensitive or resistant to VEN,and identified the activation of rAS/MAPK pathway,leading to increased stability and higher levels of MCL-1 protein,as a major acquired mechanism of VEN resistance.

关键词： acute myeloid acquired

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

表观遗传调控因子SNF5的抑癌机制研究

表观遗传调控因子SNF5的抑癌机制研究

T细胞发育、活化和癌变过程中的表观遗传调控

细胞—生命的基础——中国细胞生物学学会2013年全国学术大会·武汉

作者：赵秀娟尹洁张沛涛张弛惠伟 Boris GWilson Courtney GSansam Miriam BFWemeck Harvey Cantor charles WMroberts 王玺天津医科大学基础医学院细胞生物学系天津市医学表观遗传学协同创新中心天津市医学表观遗传学重点实验室天津市基础医学研究中心 Dana farber Cancer Institute Harvard Medical School

染色质重塑复合物SWI/SNF通过调节染色体结构从而控制基因转录、复制以及DNA损伤修复等,进而在干细胞自我复制,组织分化发育,器官形成等基本生命活动过程中发挥至关重要的作用。而近十年来的研究也揭示了SWI/SNF复合物在癌症发生发展过... 详细信息

染色质重塑复合物SWI/SNF通过调节染色体结构从而控制基因转录、复制以及DNA损伤修复等,进而在干细胞自我复制,组织分化发育,器官形成等基本生命活动过程中发挥至关重要的作用。而近十年来的研究也揭示了SWI/SNF复合物在癌症发生发展过程中的关键作用。其

关键词：表观遗传癌症 SNF5 EZH2 p53

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

T细胞发育、活化和癌变过程中的表观遗传调控

Correction: Activation of rAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

细胞—生命的基础——中国细胞生物学学会2013年全国学术大会·武汉

作者：尹洁赵秀娟黄珊历子杰路亚岚陈玉洁 Miriam BFWerneck Harvey Cantor charles WMroberts 王玺天津医科大学基础医学院细胞生物学系天津市医学表观遗传学协同创新中心天津市医学表观遗传学重点实验室天津市基础医学研究中心 Dana farber Cancer Institute Harvard Medical School

T细胞是在抗细菌/病毒感染、抗肿瘤、自身免疫、移植排斥等许多重要生理病理过程中起着关键作用的免疫细胞,T细胞自身的癌变也导致预后极差的白血病或淋巴瘤。因此,全面系统地研究T细胞发育、活化和癌变的分子机制有着极大的科学和社会... 详细信息

T细胞是在抗细菌/病毒感染、抗肿瘤、自身免疫、移植排斥等许多重要生理病理过程中起着关键作用的免疫细胞,T细胞自身的癌变也导致预后极差的白血病或淋巴瘤。因此,全面系统地研究T细胞发育、活化和癌变的分子机制有着极大的科学和社会意义。近年来,不需改变DNA序列而影响细胞生理病理状态的表观遗传调控在干细胞生物学、分化发育、及癌症发生和发展过程中的关键作用越来越多地引起重视。而且比起DNA序列改变,表观遗传变化都是可

关键词：表观遗传 T细胞发育免疫活化癌变

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2022年第5期7卷 1860-1860页

作者： Qi Zhang Bridget riley-Gillis Lina Han Yannan Jia Alessia Lodi Haijiao Zhang Saravanan Ganesan rongqing Pan Sergej N.Konoplev Shannon r.Sweeney Jeremy A.ryan Yulia Jitkova Kenneth Dunner Jr Shaun E.Grosskurth Priyanka Vijay Sujana Ghosh charles Lu Wencai Ma Stephen Kurtz Vivian r.ruvolo Helen Ma Connie C.Weng Cassandra L.ramage Natalia Baran Ce Shi Tianyu Cai richard Eric Davis Venkata L.Battula Yingchang Mi Jing Wang Courtney D.DiNardo Michael Andreeff Jeffery W.Tyner Aaron Schimmer Anthony Letai rose Ann Padua Carlos E.Bueso-ramos Stefano Tiziani Joel Leverson relja Popovic Marina Konopleva Department of Leukemia The University of Texas MD Anderson Cancer Center Houston TX USA Institute of Hematology Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China Department of Hematology The First Hospital Affiliated Harbin Medical University Harbin China AbbVie Inc. North Chicago IL USA Department of Nutritional Sciences Department of Pediatrics Department of Oncology Dell Medical School The University of Texas at Austin Austin TX 78712 USA Department of Cell Developmental & Cancer Biology Division of Hematology & Medical Oncology Knight Cancer Institute Oregon Health & Science University Portland OR USA Université de Paris Institut de la Recherche Saint-Louis (IRSL) Inserm Unit 1131 Paris France Dana-farber Cancer Institute Boston MA USA Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston TX USA Princess Margaret Cancer Center Toronto ON Canada High resolution Electron Microscopy Facility The University of Texas MD Anderson Cancer Center Houston TX USA Department of Bioinformatics & Computational Biology The University of Texas MD Anderson Cancer Center Houston TX USA Department of Lymphoma & Myeloma research The University of Texas MD Anderson Cancer Center Houston TX USA

Correction to:Signal Transduction and Targeted Therapy(2022)7:1–13,https://***/10.1038/s41392-021-00870-3 In the original version of this article,given name of 4th author Yannan Jia was incorrectly published as Yanan *** original article has been *** Access This article is licensed under a Creative Commons Attribution 4.0 International License,which permits use,sharing,adaptation,distribution and reproduction in any medium or format,as long as you give appropriate credit to the original author(s)and the source.

关键词： myeloid Therapy resistance